TB-500
A Famous Recovery Peptide, Told Honestly
TB-500 is the research-world name for synthetic thymosin beta-4, a 43-amino-acid peptide your cells already make in abundance. Its day job is directing actin, the protein skeleton cells use to move - which places it at the center of tissue repair, new blood-vessel growth, and inflammation control.
It is one of the most famous recovery peptides on the internet, half of the legendary "wolverine" pairing with BPC-157. It also left the supply in the 2023 regulatory sweep and now has one of the strongest comeback arcs in this directory.
.svg)
What we've seen in practice
Dr. Koniver is candid about where TB-500 sat in our toolkit. We used it some, and it worked - a potently anti-inflammatory peptide, very safe, one people did well with. But our results with BPC-157 were so consistent that we never reached for TB-500 as often. He says it plainly: plenty of practices call TB-500 their favorite peptide; for us it was BPC, and during the restrictions PDA. We tried it, we liked it, and BPC-157 simply proved more versatile in our hands.
Where TB-500 did earn its keep was in combinations. Paired with BPC-157 it forms the recovery stack the internet nicknamed the wolverine stack, and in Dr. Koniver's words, it works - two anti-inflammatory repair peptides coming at tissue from different angles, sometimes amplified further with GHK-copper. He also valued TB-500's immune dimension, using it in an immune combination alongside thymosin alpha-1 and LL-37, given in the evening and very well tolerated. In his tissue-repair teaching it sits among the peptides that keep tissue supple rather than rigid, which is where flexibility reputations come from.
One clarification: TB-500 and thymosin alpha-1 share a family name because both grew out of thymus research, but they are structurally unrelated molecules with different jobs - thymosin beta-4 works on tissue repair through the cell skeleton, while thymosin alpha-1 is an immune-signaling peptide. The immune-relevant behavior Dr. Koniver observed with TB-500 belongs to thymosin beta-4's own biology, not to a family resemblance.
Then came the fall of 2023, when TB-500 was placed on the federal restricted compounding list and left the regulated supply. The restriction was withdrawn in April 2026, and in July 2026 the FDA's compounding advisory committee voted 8 to 6 to recommend it for the approved compounding list.
TB-500 at a glance
Synthetic thymosin beta-4: a natural 43-amino-acid peptide, one of the most abundant small proteins in your cells, and the body's main manager of the actin cell skeleton [3]
.svg)
Tissue repair, tendon and soft-tissue recovery, flexibility, and inflammation; researched for wound healing, corneal repair, and cardiac repair
.svg)
Two decades of strong animal research; human trials exist only for topical forms (eye drops, wound gels), with mixed results; no controlled trials of injections [1, 2, 4]
.svg)
By subcutaneous injection in wellness use; the human-trial forms were topical
.svg)
43 amino acids, formula C212H350N56O78S, about 4,963 g/mol [3]
Never FDA-approved; restricted in 2023, withdrawn from that list in April 2026, recommended by the FDA's advisory committee in July 2026; prohibited in sport by WADA. Details below
A good peptide we used honestly less than its fame suggests - our recovery lead was BPC-157. See what we have seen in practice above
Green bead = the acetylated first residue (nature's own cap - the identity point the reference gets wrong). Pink beads (17-23) = the actin-binding core; some products sold as "TB-500" are only this fragment rather than the full peptide.
Acetylation makes TB-500 different
Your own thymosin beta-4 is already acetylated - TB-500 is simply the synthetic peptide
Where TB-500 comes from
Thymosin beta-4 was first characterized in the early 1980s from thymus extracts, in the laboratory tradition of Allan Goldstein that gave the thymosin family its name. The thymus connection turned out to be almost incidental: thymosin beta-4 is everywhere. It is one of the most abundant small proteins in mammalian cells, because it performs a universal job - holding actin monomers in reserve and releasing them when a cell needs to build its skeleton and move.
That job explains its repair reputation. Wound healing, blood-vessel growth, immune-cell trafficking, and tissue remodeling all depend on cells moving on cue. A peptide that governs the cell skeleton sits upstream of all of it, which is why thymosin beta-4 became a two-decade research story in wound healing, corneal repair, and cardiac recovery - and why the synthetic version acquired a fan base under the TB-500 name long before the human evidence caught up.
G-actin bound
Skeleton assembles
Cells move: repair, vessels, immune traffic
How TB-500 works
Thymosin beta-4 is the main G-actin-sequestering peptide: it binds actin monomers and controls when they polymerize into filaments. Cell movement - the first requirement of repair - runs through this switch. [3]
.svg)
By enabling endothelial and progenitor cell migration, thymosin beta-4 supports new capillary growth and the arrival of repair cells at injured tissue, alongside a damping effect on inflammatory signaling. [1, 2]
.svg)
The landmark Nature study showed integrin-linked kinase and Akt survival signaling, better cardiomyocyte survival and function in mice; pig studies showed regional thymosin beta-4 shrinking infarcts. Powerful biology - demonstrated, so far, in animals. [1, 2]
The fame runs ahead of the injected-use evidence; our observations are labeled as observations.
What the research shows
The preclinical record is genuinely strong and genuinely long: some twenty years of studies across wound healing, cornea, muscle, tendon, and heart, with the cardiac-repair work published in journals as serious as Nature and Circulation. Mechanistically, thymosin beta-4 ranks among the best-understood repair peptides anywhere.
The human record is narrower than the fame, and it comes with a twist: the real human trials are topical. Thymosin beta-4 eye drops have been through controlled trials for dry eye and neurotrophic keratopathy, and a dermal formulation has been tested for wound healing - a program that remains unapproved, with mixed results. What does not exist is a controlled human trial of injected TB-500, the form the wellness world actually uses. The reference page calls the human data "predominantly anecdotal," which is fair for injections; it simply misses the topical-trial story that does exist. Our practice experience - genuinely positive, honestly secondary to BPC-157 - lives in the clinical-observation tier, and we label it that way.
Mechanism (actin, cell migration)
Extensive laboratory research
The body's main actin manager; movement and repair biology
Well established [3]
Cardiac repair
Mouse and pig studies (Nature, Circulation)
Survival signaling, smaller infarcts, better function
Strong preclinical only [1, 2]
Wounds and cornea (topical)
Controlled human trials of eye drops and wound gels
Mixed results; no approval to date
Early human research, topical only
Injected use (the wellness form)
Practice experience; no controlled trials
Reported recovery benefits; our observations included
Clinical observation territory
How strong is the evidence
Strong animal science; the human tier is topical; injections rest on observation.
Our experience was reassuring: very anti-inflammatory, very safe in Dr. Koniver's words, with people doing well on it, and the immune combination with thymosin alpha-1 and LL-37 was very well tolerated. The published safety picture is thin but benign - injection-site effects, no red-flag pattern in the animal record.
The serious conversation is theoretical but real: a peptide whose talents include blood-vessel growth and cell migration deserves respect around cancer. That is not evidence it causes harm - it is a reason physician screening rules out active malignancy before use, a standing rule for everything we describe. We avoid it in pregnancy and breastfeeding. And the unregulated market adds its own risks: fragment products sold under the TB-500 name, and sterility and purity nobody is auditing. There is no controlled human safety database for injected use, and an honest page says so.
Regulatory status
Regulatory information current as of 13 August 2026. This is a summary, not legal or medical advice, and status can change.
Placed on restricted Category 2 - left the regulated compounding supply
Withdrawn from Category 2 - standard compounding rules apply again
Advisory committee recommends, 8-6 - advisory; final rulemaking pending
United States
RESTRICTION LIFTED
Never FDA-approved. Placed on Category 2 in the fall 2023 review; withdrawn 22 April 2026; recommended by the FDA's Pharmacy Compounding Advisory Committee, 8-6, on 23-24 July 2026 (advisory). Verify current status.
Sport (WADA)
Prohibited - S2, at all times
The Prohibited List's growth-factors class explicitly names "Thymosin-beta4 and its derivatives e.g. TB-500." Correction: the reference files it under the non-approved-substances category; the list names it in the growth-factors class. Either way: strictly off-limits for tested athletes.
Everywhere else
Not an approved medicine in any jurisdiction; a research compound worldwide, with the quality risks described in the safety section for products sold outside licensed channels.
Regulatory information current as of 13 August 2026. Verify status at publication.
Common questions
The research-market name for synthetic thymosin beta-4, a natural 43-amino-acid peptide that manages actin, the protein skeleton cells use to move. That job puts it at the center of tissue repair, blood-vessel growth, and inflammation control.
No. They share a family name from the early thymus-research era, but they are unrelated molecules: thymosin beta-4 (TB-500) works on the cell skeleton and tissue repair, while thymosin alpha-1 is an immune-signaling peptide. Dr. Koniver has used them together in an immune-support combination precisely because they do different things.
The internet's nickname for pairing BPC-157 with TB-500, two repair peptides with complementary mechanisms. In our practice the pairing worked, though Dr. Koniver's honest ranking is that BPC-157 was the stronger performer on its own, and TB-500 the supporting act.
It was placed on a restricted federal compounding list in the fall of 2023 - a regulatory decision, not a safety verdict about our experience. The restriction was withdrawn in April 2026, and in July 2026 the FDA's advisory committee recommended it for the approved compounding list. The regulatory section above has the details.
No. WADA prohibits thymosin beta-4 and names TB-500 explicitly under its growth-factors class, at all times. Tested athletes should avoid it entirely.
Related in this directory
References
- Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID 15565145.
- Hinkel R, El-Aouni C, Olson T, et al. Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection. Circulation. 2008;117(17):2232-2240. PMID 18427126.
- Molecular data: thymosin beta-4, PubChem CID 45382195, formula C212H350N56O78S, molecular weight ~4,963 g/mol.
- Regulatory and sport sources: FDA 503A bulk-substances actions (Category 2 listing 2023; withdrawal 22 April 2026; PCAC recommendation 23-24 July 2026) and the current WADA Prohibited List (growth-factors class, thymosin beta-4 and derivatives, e.g. TB-500).
Medical disclaimer: This page is for informational and educational purposes and does not constitute medical advice, diagnosis, or treatment. The FDA has not approved thymosin beta-4 (TB-500) for any use; human trials exist only for topical formulations, and injected use has no controlled human evidence base. Statements describing how Dr. Koniver and the Koniver Wellness team used TB-500 reflect clinical experience and judgment, which is not the same as controlled clinical evidence. Nothing here is a substitute for consultation with a qualified healthcare provider. Peptide therapy at Koniver Wellness is provided under physician supervision after appropriate screening, and the availability of any given peptide depends on its regulatory and supply status.
INTERESTED IN PEPTIDES?
START WITH THE RIGHT QUESTIONS.
Understand what peptides can and cannot do, what the evidence actually says, and whether physician-guided peptide therapy makes sense for you.